Resumen de acción BIM
bioMérieux S.A. desarrolla y produce soluciones de diagnóstico in vitro para el diagnóstico de enfermedades infecciosas en América, Europa, Oriente Medio, África y Asia-Pacífico.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de bioMérieux S.A.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €90.80 |
| 52 Week High | €108.90 |
| 52 Week Low | €84.54 |
| Beta | 0.15 |
| 1 Month Change | -5.32% |
| 3 Month Change | -7.40% |
| 1 Year Change | -1.67% |
| 3 Year Change | -1.35% |
| 5 Year Change | 19.63% |
| Change since IPO | 808.00% |
Noticias y actualizaciones recientes
bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
May 30
Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)
Apr 18bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings
Mar 31Recent updates
bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
May 30Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)
Apr 18bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings
Mar 31bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 17These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Mar 15bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
Jan 27bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward
Jan 06A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 16These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Oct 23bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger
Oct 05There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings
Sep 15Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Jun 30Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down
Jun 09Is bioMérieux (EPA:BIM) Using Too Much Debt?
Mar 31The Return Trends At bioMérieux (EPA:BIM) Look Promising
Feb 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jan 27bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet
Dec 16bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth
Oct 18Is bioMérieux (EPA:BIM) Using Too Much Debt?
Sep 14Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital
Aug 11An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued
Jul 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jul 05bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
May 26Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns
May 11bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year
Apr 23bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85
Apr 09bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
Mar 25Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Mar 13I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease
Feb 08Why We Like The Returns At bioMérieux (EPA:BIM)
Dec 21Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 07Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching
Nov 07Is bioMérieux (EPA:BIM) A Risky Investment?
Oct 07Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital
Sep 22Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Aug 06There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital
Jun 15A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)
May 31Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Apr 30bioMérieux (EPA:BIM) Could Easily Take On More Debt
Mar 28The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested
Mar 13Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Feb 25If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns
Feb 09If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late
Jan 20
Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?
Dec 30These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Dec 17Has bioMérieux (EPA:BIM) Got What It Takes To Become A Multi-Bagger?
Dec 03Rentabilidad de los accionistas
| BIM | FR Medical Equipment | Mercado FR | |
|---|---|---|---|
| 7D | -3.2% | -3.7% | -6.3% |
| 1Y | -1.7% | 14.0% | -2.4% |
Rentabilidad vs. Industria: BIM obtuvo unos resultados inferiores a los del sector French Medical Equipment , que el año pasado arrojó un rendimiento del 12.6%.
Rentabilidad vs. Mercado: BIM igualó el mercado French, que obtuvo un rendimiento del -2.4% el año pasado.
Volatilidad de los precios
| BIM volatility | |
|---|---|
| BIM Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in FR Market | 9.0% |
| 10% least volatile stocks in FR Market | 2.6% |
Precio estable de las acciones: BIM no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BIM (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1963 | 13,696 | Pierre Boulud | www.biomerieux.com |
bioMérieux S.A. desarrolla y produce soluciones de diagnóstico in vitro para el diagnóstico de enfermedades infecciosas en América, Europa, Oriente Medio, África y Asia-Pacífico. La empresa ofrece sistemas que utilizan muestras biológicas, como sangre, saliva, orina, etc., para el diagnóstico de enfermedades infecciosas, incluidas infecciones bacterianas, parasitarias y víricas, y el control microbiológico de la producción o del entorno de producción, principalmente para las industrias alimentaria, farmacéutica y cosmética. También ofrece un conjunto de productos y servicios de software que recopilan, analizan y fusionan diversas fuentes de datos para tomar decisiones bajo el nombre BIOMÉRIEUX VISION SUITE; diseña, fabrica y mantiene instrumentos y software; y diseña y fabrica reactivos para pruebas de diagnóstico in vitro.
Resumen de fundamentos de bioMérieux S.A.
| Estadísticas fundamentales de BIM | |
|---|---|
| Capitalización bursátil | €10.73b |
| Beneficios(TTM) | €357.60m |
| Ingresos (TTM) | €3.67b |
30.0x
Ratio precio-beneficio (PE)2.9x
Ratio precio-ventas (PS)¿Está BIM sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BIM | |
|---|---|
| Ingresos | €3.67b |
| Coste de los ingresos | €1.62b |
| Beneficio bruto | €2.06b |
| Otros gastos | €1.70b |
| Beneficios | €357.60m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
Sep 05, 2024
| Beneficios por acción (BPA) | 3.03 |
| Margen bruto | 55.99% |
| Margen de beneficio neto | 9.73% |
| Ratio deuda/patrimonio | 9.9% |
¿Cómo se ha desempeñado BIM a largo plazo?
Ver rendimiento histórico y comparativa